Company’s SARS-CoV-2 N-Protein Assay measures viral antigen in plasma, dried blood spots and saliva in more than 90 percent of COVID-19 PCR+ positive donors, including those without symptoms BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 26, 2021-- Quanterix Corporation (NASDAQ:QTRX), a company

Oral and poster presentations demonstrate the potential of company’s ultra-sensitive protein biomarker technology and assays to validate blood biomarkers as important tools for neurodegenerative disease stratification and clinical trial enrollment and efficacy BILLERICA, Mass.

Q4 GAAP revenue including Grant Revenue $26.1M ; Q4 non-GAAP revenue $21.6M , an increase of 36% versus prior year BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 2, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 25, 2021-- Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky , will be delivering a virtual

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 23, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for fourth quarter and full year 2020 after the close of trading

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 18, 2021-- Quanterix Corporation (NASDAQ: QTRX) , a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky , will be presenting at the 10 th

Partnership expands access to company’s leading biomarker technology and Simoa Accelerator Lab services into China and Asia Pacific (APAC) BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 12, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 8, 2021-- Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 4, 2021-- Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 3, 2021-- Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has commenced an underwritten public offering of $200.0 million of its common stock.